145 related articles for article (PubMed ID: 12692623)
1. Occult tumor cells detected in autologous blood stem cell harvests have no impact on 5 year outcomes for breast cancer patients with 4-9 positive nodes treated with adjuvant high-dose therapy and stem cell transplantation.
Reed E; Kessinger A; Murphy B; Tarantolo S; Traystman M; Sharp JG
Bone Marrow Transplant; 2003 Apr; 31(7):571-4. PubMed ID: 12692623
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breast cancer treated with high-dose chemotherapy and stem cell transplantation.
Solano C; Badia B; Lluch A; Marugan I; Benet I; Arbona C; Prosper F; García-Conde J
Bone Marrow Transplant; 2001 Feb; 27(3):287-93. PubMed ID: 11277176
[TBL] [Abstract][Full Text] [Related]
3. Early intensive and myeloablative adjuvant chemotherapy in women with high-risk breast cancer.
Wörmann B; Meden H; Riggert J; Humpe A; Wulf G; Koch B; Köhler M; Kuhn W; Hiddemann W
Anticancer Res; 1998; 18(3C):2237-41. PubMed ID: 9703793
[TBL] [Abstract][Full Text] [Related]
4. High-dose chemotherapy in patients with breast cancer: evaluation of infusing peripheral blood stem cells containing occult tumor cells.
Weaver CH; Moss T; Schwartzberg LS; Zhen B; West J; Rhinehart S; Campos L; Beeker T; Lautersztain L; Messino M; Buckner CD
Bone Marrow Transplant; 1998 Jun; 21(11):1117-24. PubMed ID: 9645574
[TBL] [Abstract][Full Text] [Related]
5. Analysis of dose-response relationships in the setting of high-dose ifosfamide, carboplatin, and etoposide and autologous hematopoietic stem cell transplantation: implications for the treatment of patients with advanced breast cancer.
Perkins JB; Effenbein GJ; Fields KK
Semin Oncol; 1996 Jun; 23(3 Suppl 6):42-6. PubMed ID: 8677448
[TBL] [Abstract][Full Text] [Related]
6. High-dose chemotherapy and stem cell transplantation for patients with stage IV breast cancer without clinically evident disease: correlation of CD34+ selection to clinical outcome.
Ahmed T; Kancherla R; Qureshi Z; Mittelman A; Seiter K; Mannancheril A; Puccio C; Chun HG; Bar M; Lipshutz M; Ali MF; Goldberg R; Preti R; Lake D; Durrani H; Farley T
Bone Marrow Transplant; 2000 May; 25(10):1041-5. PubMed ID: 10828863
[TBL] [Abstract][Full Text] [Related]
7. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant.
Nieto Y; Cagnoni PJ; Shpall EJ; Xu X; Murphy J; Vredenburgh J; Chao NJ; Bearman SI; Jones RB
Clin Cancer Res; 1999 Nov; 5(11):3425-31. PubMed ID: 10589754
[TBL] [Abstract][Full Text] [Related]
8. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support.
Vredenburgh JJ; Silva O; Broadwater G; Berry D; DeSombre K; Tyer C; Petros WP; Peters WP; Bast RC
Biol Blood Marrow Transplant; 1997 Jun; 3(2):91-7. PubMed ID: 9267669
[TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy (CTM) for breast cancer.
Damon LE; Wolf JL; Rugo HS; Gold E; Zander AR; Cassidy M; Cecchi G; Cohen N; Irwin D; Tracy M; Ries CA; Linker CA
Bone Marrow Transplant; 2000 Aug; 26(3):257-68. PubMed ID: 10967563
[TBL] [Abstract][Full Text] [Related]
10. Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma.
Arun B; Slack R; Gehan E; Spitzer T; Meehan KR
Cancer; 1999 Jan; 85(1):93-9. PubMed ID: 9921979
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer.
Morgan RJ; Doroshow JH; Leong L; Schriber J; Shibata S; Forman S; Hamasaki V; Margolin K; Somlo G; Alvarnas J; McNamara M; Longmate J; Raschko J; Chow W; Vasilev S; McGonigle K; Yen Y
Bone Marrow Transplant; 2001 Nov; 28(9):859-63. PubMed ID: 11781646
[TBL] [Abstract][Full Text] [Related]
12. Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial.
Yanovich S; Mitsky P; Cornetta K; Maziarz RT; Rosenfeld C; Krause DS; Lotz JP; Bitran JD; Williams S; Preti R; Somlo G; Burtness B; Mills B
Bone Marrow Transplant; 2000 Jun; 25(11):1165-74. PubMed ID: 10849529
[TBL] [Abstract][Full Text] [Related]
13. Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients.
Schulze R; Schulze M; Wischnik A; Ehnle S; Doukas K; Behr W; Ehret W; Schlimok G
Bone Marrow Transplant; 1997 Jun; 19(12):1223-8. PubMed ID: 9208116
[TBL] [Abstract][Full Text] [Related]
14. Detection of cancer cells in peripheral blood stem cells of women with breast cancer by RT-PCR and cell culture.
Krüger WH; Stockschläder M; Hennings S; Aschenbrenner M; Gruber M; Gutensohn K; Löliger C; Gieseking F; Jonat W; Zander AR
Bone Marrow Transplant; 1996 Sep; 18 Suppl 1():S18-20. PubMed ID: 8899163
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine.
Holmberg LA; Oparin DV; Gooley T; Lilleby K; Bensinger W; Reddish MA; MacLean GD; Longenecker BM; Sandmaier BM
Bone Marrow Transplant; 2000 Jun; 25(12):1233-41. PubMed ID: 10871727
[TBL] [Abstract][Full Text] [Related]
16. Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
López-Pérez R; García-Sanz R; González D; Balanzategui A; Chillón MC; Alaejos I; Mateos MV; Caballero MD; Corral M; Orfão A; González M; San Miguel JF
Bone Marrow Transplant; 2001 Oct; 28(7):665-72. PubMed ID: 11704789
[TBL] [Abstract][Full Text] [Related]
17. Positive selection and ex vivo expansion of hematopoietic progenitors as autografts for high-dose chemotherapy, potential importance in patients with bone metastases.
Purdy MH
Can J Oncol; 1995 Dec; 5 Suppl 1():63-8. PubMed ID: 8853528
[TBL] [Abstract][Full Text] [Related]
18. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation support in a patient with breast cancer metastasis to bone marrow: immunocytochemical monitoring of cancer-cell contamination].
Uno H; Fujita M; Hino N; Nakagawa H; Miyagawa H; Aoki J; Taniyama K; Sasaki N
Rinsho Ketsueki; 1999 Jul; 40(7):556-62. PubMed ID: 10483138
[TBL] [Abstract][Full Text] [Related]
19. [High-dose chemotherapy in breast cancer. Promising results in combination with stem cell support].
Ljungman P; Björkstrand B; Gahrton G; Nordenström J; Shanwell A; Glas U; Rotstein S; Rutqvist LE; Wilking N
Lakartidningen; 1995 Mar; 92(9):849, 851-3. PubMed ID: 7885111
[TBL] [Abstract][Full Text] [Related]
20. [Successful treatment with high dose chemotherapy following peripheral blood stem cell transplantation for relapsed Burkitt's lymphoma with central nervous system involvement].
Yamao H; Kondo E; Miura A; Mizuno H; Yuge M
Rinsho Ketsueki; 1998 Nov; 39(11):1121-6. PubMed ID: 9866425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]